Back to search

France· FR:66254857

TEMODAL 250 mg, gélule

A temozolomide product containing témozolomide, registered in France by MERCK SHARP & DOHME (PAYS-BAS). The same ATC class is registered in 17 of our 19 countries.

ATC L01AX03

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedTEMODAL 250 mg, géluleATCL01AX03REGISTER NO.FR:66254857PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Temozolomide is registered in 17 of 19 countries.

Countries holding a registration under ATC L01AX03 (temozolomide), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose

Temozolomide · ATC L01AX03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of temozolomide costs, country by country.

Normalised to the WHO defined daily dose (65 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Temozolomide · price per daily dose (65 mg)

USD · FX 28 Sept 2026

  • IT Italy$43.87
  • CH Switzerland$34.49
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
TÉMOZOLOMIDE
Manufacturer
MERCK SHARP & DOHME (PAYS-BAS)
Country
France (FR)
ATC code
L01AX03
ATC class
Temozolomide
Defined daily dose
65 mg, O
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400957475314
    5 sachet(s) polyéthylène basse densité (PEBD) aluminium polytéréphtalate (PET) de 1 gélule(s)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

354 interactions on record for temozolomide.

Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Temozolomide · interactions on record

354 records

  • 33 severe
  • 103 moderate
  • 16 minor
  • 202 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • CladribineL01BB04severe
  • PexidartinibL01EX15severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Temozolomide in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All temozolomide products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Cyprus · Advecit, Ridoca
  • Czechia · Temozolomide Glenmark
  • Germany · Temozo-Cell, Temozolomid Cipla
  • Denmark · Temozolomid Fair-Med, Temozolomid Stada
  • Estonia · Blastomat
  • Finland · Temozolomid Ratiopharm
  • United Kingdom (Northern Ireland) · Temozolomide, Temozolomide Crescent Pharma
  • Greece · Ridoca
  • Croatia · Temazol, Temozolomid Pgf Pharma
  • Hungary · Temozolomide Pharmacenter
  • Ireland · Temozolomide Clonmel, Temozolomide Fair-Med
  • Iceland · Temodal, Temomedac
  • Liechtenstein · Temodal, Temomedac
  • Lithuania · Blastomat
  • Latvia · Blastomat
  • Malta · Temozolomide Clonmel 100mg Hard Capsules, Temozolomide Clonmel 140mg Hard Capsules
  • Netherlands · Blastomat, Nogron
  • Norway · Temodal, Temomedac
  • Poland · Temozolomide Fair-Med, Temozolomide Glenmark
  • Portugal · Temozolomida, Temozolomide
  • Romania · Temozolomidă Hf
  • Sweden · Temozolomid Stada, Temozolomide Pgf Pharma
  • Slovakia · Temostad

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c4a797d3-3bb7-41a6-8c4b-6f0c9472fcdf
GET /v1/drugs/c4a797d3-3bb7-41a6-8c4b-6f0c9472fcdf?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66254857",
  "date_amm": "1999-01-26",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/98/096",
  "substance": "TÉMOZOLOMIDE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": "Warning disponibilité",
  "forme_pharmaceutique": "gélule",
  "voies_administration": "orale",
  "etat_commercialisation": "Non commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about temozolomide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.